Will you extrapolate EORTC 1333/PEACE-3 (enzalutamide + Rad223) to any other ARPIs for mCRPC?

Abiraterone is contraindicated in combination with Ra-223, based on the ERA 223 trial, which showed a substantial increase in fracture risk in combination with Ra-223 (29% vs. 11% with abiraterone alone). However, other ARPIs also increased fracture risk compared to ADT alone, although the extent of...

PEACE-3 was a cooperative group study of radium-223 plus enzalutamide versus enzalutamide alone in men with mCRPC. There was a significant improvement in OS (38 months vs 32 months). Most patients in the trial were previously treated with ADT monotherapy instead of intensified therapy (i.e., ADT + A...